Table 2. Antinociceptive Effects of Cannabinoids in Pre-Clinical Models of Acute Inflammatory Pain.
Pain model | Type | Treatment | Route | Species | Mechanical | Thermal | Weight bearing | Mechanism of action | Edema | Edema receptor | Citation |
---|---|---|---|---|---|---|---|---|---|---|---|
Carrageenan | Agonist | THC | p.o. | Rat | N/A | N/A | N/A | N/A | Decrease | N/A | Sofia et al, 1973 |
HU210 | i.p. | Rat | N/A | N/A | yes | CB1 | Decrease | CB1 & CB2 | Clayton et al, 2002; Elmes et al, 2005 | ||
Phytocannabinoid | THCV | i.p. | Mouse | N/A | Plantar | N/A | Non-CB | Decrease | CB2 | Bolognini et al, 2010 | |
CB1 agonist | ACEA | i.pl. | Rat | von Frey | Plantar | N/A | CB1 | N/A | N/A | Gutierrez et al, 2007 | |
CB1 PAM | ZCZ011 | i.p. | Mouse | von Frey | N/A | N/A | CB1 | No Δ | N/A | Ignatowska-Jankowska et al, 2015c | |
CB2 agonist | GW405833 | i.p. | Rat | N/A | N/A | yes | CB2 | Decrease | CB2 | Clayton et al, 2002 | |
JWH133 | i.p. | Rat | N/A | N/A | yes | CB2 | Decrease | CB2 | Elmes et al, 2005 | ||
AM1241 | i.p. | Rat | N/A | Plantar | N/A | CB2 | No Δ | N/A | Bingham et al, 2007; Nackley et al, 2003; Quartilho et al, 2003 | ||
AM1241 | i.pl. | Rat | von Frey | Plantar | N/A | CB2 | N/A | N/A | Quartilho et al, 2003 (plantar only); Gutierrez et al, 2007; Nackley et al, 2003 (von Frey and plantar) | ||
CB2 inverse agonist | JTE-907 | Mouse | N/A | N/A | N/A | N/A | Decrease | N/A | Iwamura et al, 2001 | ||
CB2 agonist + CB1 agonist | AM1241 + ACEA | i.pl. | Rat | N/A | Plantar | N/A | N/A | Decrease | CB2 | Gutierrez et al, 2007 | |
FAAH inhibition | FAAH KO | N/A | Mouse | N/A | Plantar | N/A | CB2 | Decrease | CB2 | Lichtman et al, 2004; Wise et al, 2008 | |
URB597 | i.p. | Mouse | N/A | No | N/A | N/A | Decrease | CB2 | Holt et al, 2005 (edema only); Costa et al, 2010 | ||
URB597 | i.pl. | Rat | N/A | N/A | yes | PPAR-α | No Δ | N/A | Jhaveri et al, 2008 | ||
URB937 | i.p. | Mouse | von Frey & pressure | Plantar | N/A | CB1 | Decrease | CB1 & CB2 | Clapper et al, 2010 | ||
JNJ-1661010 | Rat | N/A | Plantar | N/A | N/A | N/A | N/A | Karbarz et al, 2009 | |||
PF-3845 | i.p. | Mouse | von Frey | N/A | N/A | N/A | Decrease | N/A | Ghosh et al, 2013 | ||
MAGL inhibition | URB602 | i.p. | Mouse | N/A | Plantar | N/A | CB2 | Decrease | CB2 | Comelli et al, 2007 | |
JZL184 | i.p. | Mouse | von Frey | N/A | N/A | CB1 & CB2 | Decrease | CB2 | Ghosh et al, 2013 | ||
KML129 | i.p. | Mouse | von Frey | N/A | N/A | CB1 & CB2 | Decrease | CB2 | Ignatowska-Jankowska et al, 2014 | ||
FABP | SBFI26 | i.p. | Mouse | N/A | Plantar | N/A | N/A | Decrease | N/A | Kaczocha et al, 2014 | |
SBFI50 | i.p. | Mouse | N/A | Plantar | N/A | N/A | Decrease | N/A | Kaczocha et al, 2014 | ||
FABP5/7 KO | N/A | Mouse | N/A | Plantar | N/A | PPAR-α & TRPV1 | Decrease | N/A | Kaczocha et al, 2015 | ||
FAAH inhibition + NSAID | URB937 + Indomethacin | p.o. | Mouse | Pressure | Plantar | N/A | N/A | Decrease | N/A | Sasso et al, 2012 | |
PF-3845 + Diclofenac | i.p. | Mouse | von Frey | N/A | N/A | CB1 & CB2 | N/A | N/A | Grim et al, 2014 | ||
FAAH & MAGL inhibition | PF-3845 + JZL184 | i.p. | Mouse | von Frey | N/A | N/A | CB1 & CB2 | Decrease | CB2 | Ghosh et al, 2015 | |
SA-57 | i.p. | Mouse | von Frey | N/A | N/A | CB1 & CB2 | Decrease | CB2 | Wilkerson et al, 2017 | ||
FAAH inhibition + TRPV1 antagonism | AA-5-HT | i.p. | Mouse | Randall-Stiletto | Plantar | N/A | CB1 & TRPV1 | Decrease | TRPV1 | Costa et al, 2010 | |
FAAH inhibition + TRPV1 antagonism | AA-5-HT | i.pl. | Mouse | no | No | N/A | N/A | N/A | N/A | Costa et al, 2010 | |
FAAH & sHE inhibition | URB937 + TPPU | p.o. | Mouse | pressure | Plantar | N/A | N/A | Decrease | N/A | Sasso et al, 2015 | |
LPS (high dose) | Agonist | WIN55212-2 | i.p. | Mouse | N/A | HP | N/A | N/A | Decrease | N/A | Naidu et al, 2010 |
CP55,940 | i.p. | Mouse | N/A | HP | N/A | CB1 & CB2 | Decrease | CB2 | Kinsey et al, 2011a | ||
CB2 agonist | O-3223 | i.p. | Mouse | N/A | HP | N/A | CB2 | Decrease | CB2 | Kinsey et al, 2011a | |
LPS (high dose) | FAAH inhibition | FAAH KO | N/A | Mouse | N/A | HP | N/A | CB1 | Decrease | CB2 | Naidu et al, 2010 |
URB597 | i.p. | Mouse | N/A | HP | N/A | CB1 | Decrease | CB2 | Naidu et al, 2010 | ||
LPS (low dose) | FAAH inhibition | FAAH KO | N/A | Mouse | von Frey | N/A | N/A | CB1 & CB2 | N/A | N/A | Booker et al, 2012 |
URB597 | i.p. | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Booker et al, 2012 | ||
OL-135 | i.p. | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Booker et al, 2012 | ||
PF-3845 | i.p. | Mouse | von Frey | N/A | N/A | CB1 & CB2 | N/A | N/A | Booker et al, 2012 | ||
PF-3845 | i.pl. | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Booker et al, 2012 | ||
DAGL-β inhibition | DAGL-β KO | N/A | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Wilkerson et al, 2016a | |
KT-109 | i.p. | Mouse | von Frey | N/A | N/A | Non-CB | N/A | N/A | Wilkerson et al, 2016a | ||
KT-109 | i.pl. | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Wilkerson et al, 2016a | ||
ABHD6 inhibition | KT-195 | i.p. | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Wilkerson et al, 2016a | |
Agonist | THC | i.p. | Mouse | von Frey | N/A | N/A | N/A | N/A | N/A | Booker et al, 2012 |
Abbreviations: HP, hot plate; i.p., intraperitoneal; i.pl., intraplantar; N/A, not assessed; non-CB, not blocked by CB1 or CB2 receptors; p.o., given via gavage.